Ekspresi Survivin Dan Potensinya Sebagai Biomarker Diagnostik Dan Prognostik Pada Neoplasma Tiroid
Authors
-
Fathurrahman Tahir
Universitas Hasanuddin
-
Tarsisia Truly Djimahit
-
Upik A. Miskad
-
Dasril Daud
Keywords:
neoplasma tiroid, antiapoptosis, survivin, prognostikAbstract
Keganasan tiroid merupakan keganasan pada sistim endokrin tersering. Survivin merupakan anggota inhibitor of apoptosis protein (IAP) berperan dalam tumorigenesis melalui beberapa mekanisme yaitu menghambat apoptosis, mendorong progresi siklus sel, angiogenesis, invasi dan metastasis. Tujuan penelitian ini adalah untuk mengetahui perbedaan ekspresi survivin pada tumor jinak dan ganas asal sel folikuler tiroid dan antara tumor ganas dengan derajat differensiasi yang berbeda. Penelitian ini dilakukan dengan metode cross-sectional. Populasi penelitian adalah blok parafin sediaan lesi jinak dan ganas asal sel folikel tiroid yang tersiman di Instalasi Laboratorium Patologi Anatomi RS.Universitas Hasanuddin dan Sentra Diagnostik Patologia Makassar (SDPM) dari Januari 2016 - Desember 2017. Jumlah sampel 92 kasus terdiri dari 22 adenoma folikuler (AF) dan 70 karsinoma (21 karsinoma folikuler (KF), 37 karsinoma papiler (KP), 5 Karsinoma differensiasi buruk (KDB) dan 7 karsinoma anaplastik (KA)). Pada slide dari blok parafin yang memenuhi kriteria dilakukan pulasan imunohistokimia dengan antibodi poliklonal survivin, wild type. Perbedaan ekspresi survivin pada masing-masing kelompok diagnosis dianalisis dengan SPSS 23. Hasil penelitian menunjukkan perbedaan yang bermakna skor ekspresi survivin pada tumor jinak dengan ganas (p=0,000). Antara KP papiler dengan KDB buruk (p=0,021) dan KA (0,000) serta antara KF dengan KA (p=0,002), (p lebih kecil dari 0,05). Hasil ini menunjukkan bahwa survivin berpotensi menjadi biomarker diagnostik antara AF dengan KF serta sebagai biomarker prognostik pada keganasan tiroid
References
Altieri DC 2015. ‘Survivin - The inconvenient IAP’, Seminars in Cell and Developmental Biology. Elsevier Ltd, 39, pp. 91–96. doi: 10.1016/j.semcdb.2014.12.007.
Andrade LJO, Melo PRS, Neto WA, Andrade CS, Margotto MAS, Franca LS, and Bittencourt AMV 2013. ‘Molecular markers in Thyroid Cancer’, Revista Argentina de Endocrinologia y Metabolismo, 50(73), pp. 84–98. Available at: http://www.raem.org.ar/numeros/2013/2/84-98-Endo1-1-Andrade-B.pdf%5Cnhttp://www.embase.com
Babaei E, Vandghanooni S, Montazeri V, Eskandani M, Halimi M and Feizi MA 2011. ‘Survivin-deltaEx3: A novel biomarker for diagnosis of papillary thyroid carcinoma’, Journal of Cancer Research and Therapeutics, 7(3), p. 325. doi: 10.4103/0973-1482.87038.
Chen X, Duan N, Zhang C and Zhang W 2016. ‘Survivin and tumorigenesis: Molecular mechanisms and therapeutic strategies’, Journal of Cancer, 7(3), pp. 314–323. doi: 10.7150/jca.13332.
Chen Z, Liu N, Zhu G, Dralle H and Hoang-Vu C 2012. ‘Targeting of the anti-apoptotic gene survivin in human thyroid carcinoma’, International Journal of Molecular Medicine, 30(3), pp. 465–472. doi: 10.3892/ijmm.2012.1046.
Colnaghi R, Connell CM, Barrett RMA and Wheatley SP 2006. ‘Separating the anti-apoptotic and mitotic roles of survivin’, Journal of Biological Chemistry, 281(44), pp. 33450–33456. doi: 10.1074/jbc.C600164200.
Fortugno P, Nr W, Giodini A, Ds OC, Dcsurvivin A, Fortugno P, Dermopatico I, Wall NR, Fortugno P, Wall NR, Giodini A, Connor DSO and Plescia J 2017. ‘Plescia J , Padgett KM , Tognin S , Marchisio PC , Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function’, (March 2002).
Haghpanah V, Shooshtarizadeh P and Heshmat, R 2006. ‘Immunohistochemical Analysis of Survivin Expression in Thyroid Follicular Adenoma and Carcinoma’, Applied Immunohistochemistry, 14(4), pp. 422–425. doi: 10.1097/01.pai.0000213100.88074.b8.
Jaiswal PK, Goel A and Mittal RD 2015. ‘Survivin: A molecular biomarker in cancer’, Indian Journal of Medical Research, 141(April), pp. 389–397. doi: 10.4103/0971-5916.159250.
Jang MH, Jung KC and Min HS 2015. ‘SFN / 14-3-3 ? in Follicular Thyroid Carcinoma’, Journal of Pathology and translational Medicine, pp. 112–117.
Joanna W, Anna J, Ryszard W, Wlodzimierz L, Maciej B, Agata C, Daria B, Violet S, Marek R and Waligórska-stachura J 2012. ‘Survivin – prognostic tumor biomarker in human neoplasms – review’, Ginekol Pol, 83(7), pp. 537–540.
Katoh H, Yamashita K, Enomoto T and Watanabe M 2015. ‘Annals of Clinical Pathology Classification and General Considerations of Thyroid Cancer’, Ann Clin Pathol, 3(1), pp. 1–9.
Kementrian Kesehatan RI Pusat Data dan Informasi Kesehatan 2015. ‘Stop Kanker’, infodatin-Kanker, p. hal 3.
Kim YA, Chang M, Park YJ and Kim JE 2012. ‘Detection of survivin and COX-2 in thyroid carcinoma: Anaplastic carcinoma shows overexpression of nuclear survivin and low COX-2 expression’, Korean Journal of Pathology, 46(1), pp. 55–60. doi: 10.4132/KoreanJPathol.2012.46.1.55.
King-yin Lam A 2017. ‘Pathology of Endocrine Tumors Update: World Health Organization New Classification 2017—Other Thyroid Tumors’, 22(4), pp. 209–216. doi: 10.1097/PCR.0000000000000183.
La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F and Negri E 2015. ‘Thyroid cancer mortality and incidence: A global overview’, International Journal of Cancer, 136(9), pp. 2187–2195. doi: 10.1002/ijc.29251.
Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC and Altieri DC 1998. ‘Control of apoptosis and mitotic spindle checkpoint by survivin.’, Nature, 396(6711), pp. 580–584. doi: 10.1038/25141.
Li JY, Shi J, Sang JF, Yao YZ, Wang XC and Su L 2015. ‘Role of survivin in the pathogenesis of papillary thyroid carcinoma’, Genetics and Molecular Research, pp. 15102–15111. doi: 10.4238/2015.November.24.19.
Li Volsi VA 2011. ‘Papillary thyroid carcinoma: an update’, Modern Pathology. Nature Publishing Group, 24(S2), pp. S1–S9. doi: 10.1038/modpathol.2010.129.
Mckenzie JA and Grossman D 2012. ‘Role of the apoptotic and mitotic regulator survivin in melanoma’, Anticancer Research, 32(2), pp. 397–404.
Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T and Altieri DC 2010. ‘IAP Regulation of Metastasis’, Cancer Cell. Elsevier Ltd, 17(1), pp. 53–64. doi: 10.1016/j.ccr.2009.11.021.
Mita AC, Mita MM, Nawrocki ST and Giles FJ 2008. ‘Survivin: Key regulator of mitosis and apoptosis and novel target for cancer therapeutics’, Clinical Cancer Research, 14(16), pp. 5000–5005. doi: 10.1158/1078-0432.CCR-08-0746.
Pannone G, Santoro A, Pasquali D, Zamparese R, Mattoni M, Russo G, Landriscina M, Piscazzi A, Toti P, Cignarelli M, Lo Muzio L and Bufo P 2014. ‘The Role of Survivin in Thyroid Tumors: Differences of Expression in Well-Differentiated, Non–Well-Differentiated, and Anaplastic Thyroid Cancers’, Thyroid, 24(3), pp. 511–519. doi: 10.1089/thy.2013.0196.
Sanhueza C, Wehinger S, Castillo Bennett, J, Valenzuela M, Owen GI and Quest AFG 2015. ‘The twisted survivin connection to angiogenesis’, Molecular Cancer. Molecular Cancer, 14(1), p. 198. doi: 10.1186/s12943-015-0467-1.
Scopa CD 2004. ‘Histopathology of thyroid tumors. An overview.’, Hormones (Athens, Greece), 3(2), pp. 100–110. doi: 10.14310/horm.2002.11118.
Šelemetjev S, Cveji? D, Savin S, Paunovi? I and Tati? S 2011. ‘Survivin in relation to Bcl-2, Bax and in Situ apoptotic cell death in anaplastic thyroid carcinoma’, Archives of Biological Sciences, 63(4), pp. 955–964. doi: 10.2298/ABS1104955S.
T.A., W., D., D., I., N., J.C., R., S., M., P.E., V., K., R., S.A., T., W.T., K. and A., K. (2017) ‘Survivin and XIAP - Two potential biological targets in follicular thyroid cancer’, European Surgical Research, 58(February), pp. 15–18. doi: 10.1159/000463597.
Waligórska-Stachura J, Andrusiewicz M, Sawicka-Gutaj N, Biczysko M, Jankowska A, Kubiczak M, Czarnywojtek A, Wrotkowska E and Rucha?a M 2014. ‘Survivin delta Ex3 overexpression in thyroid malignancies’, PLoS ONE. doi: 10.1371/journal.pone.0100534.
Waligórska-Stachura J, Sawicka-Gutaj N, Zabel M, Andrusiewicz M, Gut P, Czarnywojtek A and Rucha?a M 2017. ‘Survivin DEx3 as a biomarker of thyroid cancers: A study at the mRNA and protein level’, Oncology Letters, pp. 2437–2441. doi: 10.3892/ol.2017.5713.
Zhang HY, Meng X, Du ZX, Fang CQ, Liu GL, Wang HQ and Deng WW 2009. ‘Significance of survivin, caspase-3, and VEGF expression in thyroid carcinoma’, Clinical and Experimental Medicine, 9(3), pp. 207–213. doi: 10.1007/s10238-009-0031-7.
